Comparative Pharmacology
Head-to-head clinical analysis: SULF 10 versus SULFA TRIPLE 2.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULF 10 versus SULFA TRIPLE 2.
SULF-10 vs SULFA-TRIPLE #2
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfacetamide inhibits bacterial dihydropteroate synthase, blocking folate synthesis and thereby nucleic acid production.
The sulfonamides (sulfamethazine, sulfathiazole, sulfamerazine) act as competitive inhibitors of para-aminobenzoic acid (PABA) utilization in bacterial dihydrofolate synthesis, thereby inhibiting folic acid synthesis and bacterial growth.
One to two drops of SULF-10 ophthalmic solution (10% sulfacetamide sodium) instilled into the affected eye(s) every 2-3 hours initially, then decreasing frequency as infection resolves, up to 5-6 times daily.
2 tablets orally every 4 hours initially, then 2 tablets every 6 hours thereafter. Each tablet contains 167 mg sulfadiazine, 167 mg sulfamerazine, and 167 mg sulfamethazine (total sulfonamide 500 mg per tablet).
None Documented
None Documented
Terminal elimination half-life is 7-12 hours in adults with normal renal function; prolonged in renal impairment
Sulfadiazine: 10-16 hours; Sulfamerazine: 15-24 hours; Sulfamethazine: 12-24 hours. The combined half-life is approximately 15-20 hours in patients with normal renal function, requiring dosing every 12-24 hours.
Renal excretion of unchanged drug and acetylated metabolites: ~85-90%; biliary/fecal: ~10-15%
Renal (approximately 70-80% as unchanged sulfonamides via glomerular filtration and tubular secretion); biliary/fecal (approximately 20-30% as metabolites).
Category C
Category C
Antibiotic (Sulfonamide)
Antibiotic (Sulfonamide)